Compare COSM & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COSM | JSPR |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Other Pharmaceuticals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8M | 14.9M |
| IPO Year | 2009 | N/A |
| Metric | COSM | JSPR |
|---|---|---|
| Price | $0.25 | $0.49 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | ★ 1.2M | 566.3K |
| Earning Date | 04-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.15 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $65,271,815.00 | N/A |
| Revenue This Year | $54.08 | N/A |
| Revenue Next Year | $32.66 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.93 | N/A |
| 52 Week Low | $0.25 | $0.43 |
| 52 Week High | $1.32 | $7.19 |
| Indicator | COSM | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 38.07 | 25.07 |
| Support Level | $0.25 | N/A |
| Resistance Level | $0.41 | $1.06 |
| Average True Range (ATR) | 0.02 | 0.11 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 4.25 | 10.26 |
Cosmos Health Inc is a diversified, vertically integrated healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of medicines and repurposing drugs as well as operator of a telehealth platform. The company has developed its own proprietary branded nutraceutical products, named 'Sky Premium Life' and 'Mediterranation'. Its product portfolio includes generics and over-the-counter pharmaceutical products, medicines, as well as nutraceuticals and biocides. The company's Reportable segments are Wholesale, Pharma manufacturing, and Nutraceutical and pharmaceuticals, with the majority of revenue generated from the Wholesale segment.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.